Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
CA 2297692 A1 · Owner: Innogenetics N.V. · Inventors: Sablon, Erwin; Buyse, Marie-Ange
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns molecules which bind and neutralize the cytokine interferon-gamma. More specifically the present invention relates to , sheep-derived antibodies and engineered antibody constructs such as humanized , single-chain Fv fragments chimeric antibodies, diabodies, triabodies tetravalent antibodies, peptabodies and hexabodies which can be used to treat diseases wherein interferon-gamma activity is pathogenic. Examples of such diseases are: septic shock, cachexia, multiple sclerosis and psoriasis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 14, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 14, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 14, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.